Exelixis Inc (EXEL) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

Total Cash From Operating Activities Chart for Exelixis Inc

Exelixis Inc (EXEL) operating cash flow for FY2025 was USD 884.3M, a 26.3% change from FY2024. Exelixis Inc's operating cash flow moved from USD -7.3M in 1999 to USD 884.3M in 2025 over 26 years. Operating cash flow compound annual growth rate: 5-year CAGR of 33.4%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$17.19B
Implied Share Price
$69.39
Enterprise Value
$15.75B
Revenue (TTM)
$2.44B
EBITDA
$1.02B
Profit Margin
35.33%
Trailing P/E
21.89
Forward P/E
15.46
Price/Book (MRQ)
8.91
Price/Sales (TTM)
7.06
EV/EBITDA
15.43
EV/Revenue
6.46
Dividend Yield
—
Book Value
$8.23
Free Cash Flow (FY2025)
$844.34M
Free Cash Flow Yield
4.91%

Snapshot as of 30th October 2026 — not point-in-time controlled, may lag the live market by a few days.